onc brain

All studies · 109

• New 🌰 Prostate · 2026-07-22
  ESTRO Prostate SBRT Consensus Recommendations
  15-expert ESTRO Delphi consensus on optimising primary prostate SBRT: patient selection, contouring, dose/fractionation, follow-up, and delivery technique.
• New 🌰 Prostate · 2026-07-22
  ProtecT (secondary analysis: cribriform morphology)
  Cribriform-negative pts (87%): radical Rx gave no significant 15yr metastasis reduction vs active monitoring; cribriform-negative GG2 matched GG1 risk.
• New 🟡 Hepatobiliary · 2026-07-20
  NRG Oncology/RTOG 0848
  OS primary EP not met (HR 0.96, 90% CI 0.79-1.18) adding adjuvant CXRT to gemcitabine; node-negative subgroup OS benefit on interaction (P=.0063).
• New 🌰 Prostate · 2026-07-19
  TROG 08.03 RAVES QOL Substudy
  At 5yr, 16% vs 2% severe urinary leakage aRT vs no RT (p=0.01); sRT timing had no QOL effect.
• New 🚀 Practice-changing 🌰 Prostate · 2026-07-15
  STAMPEDE (abiraterone ± enzalutamide, high-risk non-metastatic)
  MFS HR 0.53 (6yr 82% vs 69%) and OS HR 0.60 adding 2yr abiraterone to ADT in high-risk M0 prostate (85% also had RT).
• New 🫁 Thoracic / Lung · 2026-07-14
  TREASURE
  mOS 6.7 vs 13.4mo (HR 1.55, ns) adding consolidative TRT to atezo maintenance; halted early for SAEs 61% vs 18%.
• New 🧠 CNS · 2026-07-13
  EANO Consensus Statement on Radiation Necrosis
  Delphi consensus (20 experts): 53/57 statements reached ≥80% agreement; perfusion MRI + amino-acid PET to distinguish RN from recurrence, bevacizumab for steroid-refractory RN.
• New 🌰 Prostate · 2026-07-09
  HYDRA
  No PFS difference vs conventional RT for either MHFRT type, but dose-escalated MHFRT alone raised late G2+ GI + bowel-QoL decrement; isodose 60/20 clean.
• New 🌰 Prostate · 2026-07-09
  ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate Cancer
  Modern 5-fraction SBRT (1-2% bothersome toxicity vs 10-30% for 2D-era 45fx) is now NCCN-endorsed for UIR prostate; focal-boost de-escalation is next.
• New 🎀 Breast · 2026-07-09
  SUPREMO
  10yr chest-wall recurrence 1.1% vs 2.5% (HR 0.45), no DFS/OS gain, but trial prohibited RNI so tests incomplete PMRT.
• New 👄 Head & Neck · 2026-07-08
  ESTRO Oral Cavity CTV Delineation Guidelines
  New consensus recipe for post-op CTV: recreate pre-op GTV-P +10mm composited with surgical defect/flap +5mm; standardizes OCSCC delineation at EQD2 60 Gy.
• New 🌰 Prostate · 2026-07-08
  10-yr SBRT for Prostate Cancer (Meier Nonrandomized Trial)
  10-yr OS 84%, RFS 90% (94% LR, 86% IR); late G3 GU/GI ≤1.5%, no G4-5; 40Gy/5fx SBRT, no ADT, 21 centers
• New 🌰 Prostate · 2026-07-08
  American Radium Society AUC: Intraprostatic Recurrence After RT
  PSMA PET + mpMRI plus mandatory pre-salvage biopsy, then reirradiation (≤6 fx) over ADT alone, for radiorecurrent intraprostatic disease.
• New 🌰 Prostate · 2026-07-08
  NRG-GU005
  DFS superiority not met (HR 1.38, futility crossed); SBRT improved 2y bowel QoL (35% vs 44% MCID decline, p=0.034) vs MH-IMRT.
• New 🎀 Breast · 2026-07-07
  SUPREMO
  10-yr OS 81.4% vs 81.9% (HR 1.04, P=0.80): chest-wall RT gives no OS benefit in intermediate-risk post-mastectomy breast cancer.
• New 🌰 Prostate · 2026-07-07
  ARTO
  mOS NR vs 50mo, HR 0.55 (0.33-0.92, p=0.021) adding SBRT to all mets to abi+ADT in oligomet CRPC (unplanned OS analysis).
• New 🧠 CNS · 2026-07-07
  EORTC 22033-26033
  No PFS/OS difference between first-line RT and TMZ in high-risk WHO grade 2 LGG; only IDH-wildtype favored TMZ (HR 0.47).
• New 👄 Head & Neck · 2026-07-01
  ReCOG/ESTRO/ASTRO HNSCC Reirradiation Consensus
  Expert consensus on reRT for recurrent/2nd-primary HNSCC in previously irradiated fields; 17-panel vote, guidance on selection, delineation, dose accumulation, toxicity.
• New 🟡 Hepatobiliary · 2026-07-01
  NRG/RTOG 1112
  Adding SBRT to sorafenib: mOS 15.8 vs 12.3mo (HR 0.77, 1-sided P=.06, ns primary); mPFS 9.2 vs 5.5mo, HR 0.55, P<.001.
• New 💧 Bladder · 2026-06-29 ASTRO Annual Meeting 2025
  BART
  2y locoregional FFS 87.1% vs 76.0% (HR 0.43, p=0.04) with adjuvant pelvic RT post-cystectomy; OS not significant (HR 0.78, p=0.31).
• New 🌰 Prostate · 2026-06-25
  ENZARAD (ANZUP 1303)
  MFS 8yr 74% vs 72%, HR 0.88 (0.67-1.15) p=0.34; enza on an RT+ADT backbone missed 1° endpoint, benefit isolated to cN1/pelvic-RT.
• New 🌀 GI Lower · 2026-06-21
  ARS Appropriate Use Criteria for Locoregionally Recurrent Rectal Cancer
  Guideline update, 116 studies: margin-negative (R0) resection determines survival; preop systemic ± RT/reirradiation enables downsizing, no major practice change.
• New 🌰 Prostate · 2026-06-18
  PRIMARY2
  Non-inferior csPCa detection (12% vs 16%, diff -3.7%) with PSMA-PET biopsy triage, avoiding biopsy in 49% of equivocal/negative-MRI men.
• New 💧 Bladder · 2026-06-17
  INDIBLADE
  2yr bladder-intact EFS 78% (67-90%) with induction ipi+nivo before chemoRT; 2yr OS 96% in cT2-4aN0-2 MIBC.
• New 🦴 Sarcoma · 2026-06-16
  DOREMY
  5yr local recurrence-free survival 97.4% after de-escalated 36Gy/18fx preop RT in myxoid liposarcoma; wound complications 21%.
• New 🌰 Prostate · 2026-06-16
  REVELUTION
  68.9 mm³ greater total coronary plaque progression with leuprolide vs relugolix at 12mo (adjusted), non-metastatic prostate on RT + ADT.
• New 👄 Head & Neck · 2026-06-15
  KEYNOTE-689 vs NIVOPOSTOP
  Round-up of two positive phase 3 IO trials in resectable LA-HNSCC: perioperative pembro and post-op nivo added to adjuvant CRT.
• New 🎀 Breast · 2026-06-14
  GEC-ESTRO APBI Patient Selection Recommendations
  Expanded APBI eligibility: now unifocal/multifocal ≤2cm, pTis/T1-2 ≤30mm, pN0/pN1mi, all histologies; BRCA1-2, TNBC, ≥pN1a, age <40 contraindicated.
• New 🌰 Prostate · 2026-06-12
  ORIOLE
  6-mo progression 19% vs 61% favoring SABR (P=.005); mPFS NR vs 5.8mo, HR 0.30 (0.11-0.81) in oligomet HSPC.
• New 🌰 Prostate · 2026-06-12
  RADIOSA
  mcPFS 32.2 vs 15.1mo, HR 0.43 (0.26-0.72), p=0.001 adding 6mo ADT to metastasis-directed SBRT in oligorecurrent HSPC.
• New 🌰 Prostate · 2026-06-12
  WOLVERINE
  PFS HR 0.44, rPFS HR 0.60 favor MDT added to SOC in oligomet prostate; OS HR 0.63 non-sig (p=0.051).
• New 🌰 Prostate · 2026-06-12
  ARTO
  Adding SBRT to abiraterone lifted 6-mo PSA response to 92% vs 68.3% (OR 5.34) and cut progression (PFS HR 0.35) in oligomet CRPC.
• New 🌰 Prostate · 2026-06-12
  EAU 2026: What Evidence Do We Have from Intensification with SBRT?
  MDT/SBRT delays progression in oligorecurrent HSPC; ARTO the lone randomized OS signal (CRPC); de novo evidence pending (STAMPEDE2).
• New 🟡 Hepatobiliary · 2026-06-10
  NRG Oncology/RTOG 0848
  OS HR 0.96 (90% CI 0.79-1.18), p=0.38: adjuvant chemoRT adds no OS benefit over chemo alone after pancreatic head resection.
• New 🧠 CNS · 2026-06-09
  FIRESTORM
  5-yr PFS 65.8% vs 38.8% favoring dose-escalated RT (BED ≥79.2 Gy), HR 0.40; OS not improved.
• New 🧠 CNS · 2026-06-09
  RTOG 0539
  10-yr PFS 72.2% intermediate-risk (54Gy) and 42.5% high-risk (60Gy) meningioma on adjuvant RT; low-risk observed 85.2%.
• New 🎀 Breast · 2026-06-09
  RAPCHEM
  10-yr locoregional recurrence 2.9% (24/838) with radiotherapy de-escalated by nodal response to neoadjuvant chemo; no comparator arm.
• New 🌰 Prostate · 2026-06-04 ASCO Annual Meeting 2026
  MROQC ADT Practice Patterns
  Guideline-concordant ADT (≥18mo) recommended in 67.0% of high-risk pts on definitive RT; ARPI intensification just 23.2% of STAMPEDE-eligible.
• New 👄 Head & Neck · 2026-06-04 ASCO Annual Meeting 2026
  AREST
  3-yr LRFS 89.2% vs 80.9%, HR 0.52 (0.30-0.91) p=0.02 favoring adjuvant RT in resected intermediate-risk pT1-2N0 oral SCC; no OS/DFS gain.
• New 🎀 Breast · 2026-06-02 ASCO Annual Meeting 2026
  Concurrent Systemic Therapy + Radiation Timing (Speers)
  Traffic-light framework for what runs concurrent with breast/CW + RNI RT vs hold: continue endocrine + trastuzumab/pertuzumab, caution T-DXd/CDK4/6i, hold cytotoxics/PARPi.
• New 🌀 GI Lower · 2026-06-02 ASCO Annual Meeting 2026
  mRCAT-III
  pCR 61.0% vs 28.6% (P<0.0001) with node-sparing SCRT + tislelizumab + CAPOX vs conventional SCRT + CAPOX in pMMR LARC.
• New 🫁 Thoracic / Lung · 2026-06-02 ASCO Annual Meeting 2026
  LBA8005: Concurrent Thoracic RT + Chemoimmunotherapy in ES-SCLC
  OS 10.0 vs 11.8 mo, HR 1.14 (0.84-1.56), p=0.40: concurrent thoracic RT added no benefit to durvalumab-based chemoIO in ES-SCLC.
• New 🌀 GI Lower · 2026-06-01 ASCO Annual Meeting 2026
  ctDNA and Local Regrowth/Distant Mets in Nonoperative Management of Stage II-III Rectal Cancer
  ctDNA sensitivity 41% for local regrowth vs 74% for distant mets; positive result predicts both but can't replace endoscopy/MRI surveillance in rectal NOM.
• New 🫁 Thoracic / Lung · 2026-06-01 ASCO Annual Meeting 2026
  DeLLphi-304
  Intracranial: time-to-CNS-progression HR 0.54 ITT; in brain-mets pts CNS PFS 6.5 vs 4.2mo (HR 0.40), CNS CR 15% vs 5% for tarlatamab.
• New 🌰 Prostate · 2026-05-31
  COMPPARE
  Proton vs IMRT: no difference in bowel urgency (6% vs 5.7%), ≥G2 GI tox, or 3-yr biochemical control in localized prostate.
• New 🌰 Prostate · 2026-05-31
  PROTEUS
  Most distant mets PSMA PET-detected (53.0% APA vs 60.7% control); preview NEJM data, MFS benefit's clinical meaning contested.
• New 🌰 Prostate · 2026-05-31
  CAN-2409
  DFS HR 0.70 (0.52-0.94, p=0.016) adding intraprostatic CAN-2409 to EBRT in intermediate/high-risk localised prostate; OS and PCSM immature.
• New 🚀 Practice-changing 🍽️ GI Upper · 2026-05-31
  RASolute 302
  mOS 13.2 vs 6.7mo, HR 0.40 (0.30-0.53), P<0.001 for daraxonrasib vs investigator's-choice chemo in previously treated metastatic pancreatic cancer.
• New 🌀 GI Lower · 2026-05-31
  MIRACLE-2
  68% ORR, mOS 23.2mo, 18% NED with RT-primed chemo + tislelizumab in MSS unresectable met rectal ca.
• New 🫁 Thoracic / Lung · 2026-05-31
  OCEANUS
  Sequential iRT beat concurrent for real-world OS in newly-dx advanced NSCLC: median 20.3 vs 16.0 mo, HR 0.68 (0.47-0.99), P=.045.
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  RAD-IO
  12-mo DFS 40/50 (80%, 95% CI 0.67-0.89) cleared the pre-set ≥75% GO bar for durvalumab added to 5FU/MMC chemoRT in MIBC.
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  Management of MIBC After Pathologic Complete Response
  Review of perioperative MIBC management after pCR: sandwich IO regimens continue adjuvant regardless of response, cisplatin-chemo alone moves to surveillance.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  Genomic Classifier + NCCN Risk Stratification (Abstract 5000)
  22-gene GC independently prognostic (MFS/DM/OS, p<0.001); combined NCCN+GC score reclassifies ~¼ of high-risk pts to gate AAP intensification on an RT+ADT backbone.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  A-DREAM
  41% remained treatment-free with eugonadal testosterone recovery at 18mo after interrupting ADT+ARPI in deep-responding mHSPC (1° EP met, one-sided p=0.0249).
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  ARACOG (AFT-47)
  MCCD -36.1 (enza) vs -15.8 (daro), P=0.009 at 24 wk: enzalutamide worse for cognition; randomized open-label phase 2, N=111 advanced prostate.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  Precision Oncology: Applying New Biomarkers in GU Cancers
  Biomarker round-up: tissue HRR/tumor-suppressor testing is SOC, but genomic classifiers show 24% clinical-risk discordance and lack ARPI-era validation.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  ENZAMET + Decipher (Part 2)
  Decipher >0.85 predicts docetaxel OS benefit on an ADT+enza backbone (HR 0.75 vs 1.94, interaction p=0.04); ≤0.85 can skip docetaxel.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  TALAPRO-3
  3yr rPFS 77% vs 56%, HR 0.48 (0.36-0.65), adding talazoparib to enzalutamide/ADT in HRR-deficient metastatic prostate cancer.
• New 🎀 Breast · 2026-05-30 ASCO Annual Meeting 2026
  PREPEC
  Pre-pectoral implant improved 2yr chest well-being +4.8 pts (BREAST-Q, p=0.01) vs sub-pectoral, but more unplanned implant loss (21% vs 15%).
• New 🧠 CNS · 2026-05-30 ASCO Annual Meeting 2026
  ROADS
  Surgical bed recurrence 1% vs 12% and 2yr OS 62% vs 36% favoring intraoperative GammaTile brachytherapy over post-op SRS for resected brain mets >2cm.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  CHRYSALIS-2
  mOS 41.0 mo (95% CI 27.7-NE) with 1L amivantamab + lazertinib in treatment-naïve atypical EGFR-mutant NSCLC; single-arm, n=49.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  ESAONA
  iORR 95.5% vs 79.6% (p=0.0004) and icPFS HR 0.46 favoring asandeutertinib over osimertinib in 1L EGFR-mut NSCLC brain mets.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  OptiTROP-Lung05
  mPFS NR vs 5.7 mo, HR 0.35, adding Sac-TMT (TROP2 ADC) to pembrolizumab in 1L PD-L1+ NSCLC.
• New ♂️ Germ Cell / Other GU · 2026-05-30 ASCO Annual Meeting 2026
  Living Longer, Living Better: Can We Have It All?
  ASCO26 GU discussant on curative-intent trade-offs: bladder-sparing chemoRT + IO feasibility, and ctDNA over pathology for adjuvant RCC selection.
• New 🍽️ GI Upper · 2026-05-30 ASCO Annual Meeting 2026
  Neo-CRAG
  Adding neoadjuvant chemoRT (45Gy/25fx) to periop XELOX improved mDFS 52.7 vs 24.4mo (HR 0.75) and mOS 67.5 vs 37.6mo in high-risk LAGC.
• New 🤝 Supportive / QoL · 2026-05-30 ASCO Annual Meeting 2026
  SPIN Score (Celiac Plexus SRS)
  89% pain response at SPIN 2 vs 32% at SPIN 0 for celiac SRS; post-hoc selection score, n=90.
• New 🧠 CNS · 2026-05-29 ASCO Annual Meeting 2026
  Wait or Treat?
  Upfront cranial RT cut 2y intracranial progression (21.7% vs 50%, sub-HR 0.35) but no OS gain; survival numerically favored delayed (HR 1.45).
• New 🎀 Breast · 2026-05-27
  SENOMAC
  5-yr RFS 89.7% vs 88.7%, HR 0.89 (0.66-1.19): omitting completion ALND noninferior, with nodal RT given in ~90% of both arms.
• New 🫁 Thoracic / Lung · 2026-05-26
  SWOG/NRG S1914
  OS HR 1.15 (0.65-2.01), p=0.63: adding atezolizumab to SBRT did not improve survival in early-stage inoperable NSCLC; futility-stopped, excess toxicity.
• New 🌞 Skin / Melanoma · 2026-05-22
  EORTC Cutaneous Lymphoma RT Recommendations
  Low-dose RT (8-12 Gy) recommended for indolent cutaneous lymphomas; MF 1-yr local control ≥92%, but no RCT defines a standard dose per entity.
• New 🎀 Breast · 2026-05-22
  DBCG IMN2
  15yr OS 65.0% vs 60.8% with IMNI, adjusted HR 0.85 (0.76-0.94); benefit persists under modern systemic therapy and 3D RT.
• New 🌰 Prostate · 2026-05-22
  PEACE V-STORM
  4-yr MFS 76% vs 63% favoring ENRT over MDT for pelvic nodal oligorecurrence, HR 0·62 (80% CI 0·44-0·86, p=0·063).
• New 🎀 Breast · 2026-05-21
  SWOG S1007
  5y LRR 0.55% without RNI vs 0.85% with; IDFS unchanged by RNI (HR 1.03 premenopausal, 0.85 postmenopausal) in RS ≤25 N1 breast.
• New 🎀 Breast · 2026-05-21
  EORTC 22922/10925
  20yr OS 61.0% vs 61.8%, HR 1.00 (p=.967): IM-MS-RT cut breast cancer mortality (HR 0.82) but raised non-BC deaths (HR 1.26).
• New 💧 Bladder · 2026-05-21
  Bladder Adjuvant Radiotherapy Trial
  2y LRFS 87.1% vs 76.0%, HR 0.43 (0.20-0.96) P=.04 favoring adjuvant pelvic IMRT after cystectomy; DFS/BCSS/OS all NS.
• New 🎀 Breast · 2026-05-20
  Proton vs Photon PMRT Capsular Contracture
  Proton PMRT trended toward higher capsular contracture vs IMRT photon (univariate HR 2.3; MVA HR 1.76 ns); proton+DTI worst, 50% 2yr CC.
• New 🎀 Breast · 2026-05-20
  NRG/RTOG 9804 + E5194 Combined Analysis
  15-yr IBR 11.4% vs 19.0% with vs without tamoxifen in RT-omitted good-risk DCIS; MVA HR 0.54, invasive-IBR HR 0.43.
• New 🫁 Thoracic / Lung · 2026-05-20
  High-Dose Hyperfractionated SIB RT vs Standard RT for LS-SCLC
  mOS 60.7 vs 39.5mo, HR 0.55 (0.37-0.72), p=0.003 favoring dose-escalated 54Gy BID SIB over standard 45Gy BID in LS-SCLC.
• New 💧 Bladder · 2026-05-19 ESTRO Congress 2026
  Multicenter TMT Bladder Preservation Analysis (n=369)
  CLR 63.7% in 369 MIBC pts on definitive TMT; 5-FU-based CRT and better image guidance predicted higher complete local response.
• New 🫁 Thoracic / Lung · 2026-05-19 ESTRO Congress 2026
  Single-fraction SABR for primary NSCLC and lung oligomets (pooled, n=1687)
  2-yr local control 90-93% and G3+ AEs 2-3% across 1687 pts (1200 primary NSCLC, 487 oligomets) treated with single-fraction SABR.
• New 🌰 Prostate · 2026-05-19 ESTRO Congress 2026
  AUA 2026: ePLND / PSMA PET staging round-up
  PSMA PET NPV ~96% may safely omit ePLND in intermediate-risk pts; 47.7% of nodal mets fall outside the ePLND template.
• New 🌀 GI Lower · 2026-05-18 ESTRO Congress 2026
  OPERA Trial (5-year)
  76% achieved a good clinical response at W14 (DRE+rectoscopy); nCR matched cCR for 5yr organ preservation (77% vs 81%), enabling early W&W selection.
• New 🌰 Prostate · 2026-05-18 ESTRO Congress 2026
  HEAT Trial
  AHRT 5fx non-inferior to EHRT 26fx for biochemical failure, 7% vs 7.4% (P_NI=0.007) at 4.25y; less acute GI toxicity.
• New 🌰 Prostate · 2026-05-18 ESTRO Congress 2026
  PEACE 2
  Pelvic nodal RT missed 1° endpoint: 7yr cPFS 67.1% vs 62.9% prostate-only, HR 0.81 (0.63-1.03) p=0.088; no MFS/PCSS/OS gain.
• New 👄 Head & Neck · 2026-05-18 ESTRO Congress 2026
  TORPEdO
  UW-QoL physical composite similar IMPT vs IMRT at 3/12/24mo in OPSCC; no proton QoL-toxicity benefit (no effect size reported in source).
• New 👄 Head & Neck · 2026-05-18 ESTRO Congress 2026
  Proton versus photon therapy for oropharyngeal cancer
  Lancet correspondence on proton vs photon for oropharynx; no effect sizes reported in source (title/citation only).
• New 👄 Head & Neck · 2026-05-18 ESTRO Congress 2026
  INRT-AIR & DARTBOARD pooled analysis
  5-yr solitary elective nodal recurrence 0% with ENI omission across 117 pts; 5-yr OS 87%, PFS 74%.
• New 🟡 Hepatobiliary · 2026-05-18 ESTRO Congress 2026
  Multinational HCC EBRT IPD Cohort
  Median OS 6.8y BCLC-0 and 4.6y BCLC-A across 4,913 EBRT-treated HCC pts, comparable to resection/ablation.
• New 🎯 Oligometastatic / Mets · 2026-05-18 ESTRO Congress 2026
  EXTEND Trial
  MDT+SOC improved PFS across all baskets, HR 0.54 (0.41-0.72), p<0.001; RT delivered 98% of MDT.
• New 🫘 Kidney · 2026-05-18 ESTRO Congress 2026
  FASTRACK II
  100% freedom from local progression at 36, 60, and 84 months after single-fraction 26 Gy or 42 Gy/3fx SABR in inoperable primary RCC.
• New 🎀 Breast · 2026-05-18 ESTRO Congress 2026
  NRG/RTOG 1005
  7-yr IBR 2.6% vs 2.2%, HR 1.31 (90% CI 0.84-2.04): concurrent boost noninferior to sequential, cutting WBI+boost to 15 fractions.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  POP-RT vs PEACE-2
  WPRT bFFS HR 0.50 in POP-RT vs bPFS HR 0.97 in PEACE-2; pelvic nodal RT benefit vanishes with 3yr ADT and higher prostate dose.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PRIME
  Interim data: 36.25 Gy/5 fx SBRT with whole-pelvis RT and 2y ADT shows no inferiority signal vs 68 Gy/25 fx; BFFS immature.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PIVOTALboost
  Late 2yr G2+ bowel 8.2% / 8.7% / 6.5% and bladder 19.5% / 24.1% / 16.5% across prostate, +boost, +pelvic nodes arms.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PACE-NODES
  Grade ≥2 GI toxicity 28% vs 21% with added pelvic nodal SBRT over 12wk; GU unchanged, symptoms resolved by 12wk.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PEACE-2
  7yr cPFS 67.1% pelvic vs 62.9% prostate-only RT, HR 0.81 (0.63-1.03), p=0.088: primary endpoint not met.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  RADIOSA (MFS post-hoc)
  Post-hoc MFS 16.6mo vs not reached, HR 0.39 favoring SBRT + 6mo ADT over SBRT alone in oligorecurrent prostate.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  OLIGOMA
  mPFS 35.8 vs 20.4mo, HR 0.48 (0.25-0.91), p=0.021 for MDT to all lesions in oligometastatic breast, QoL non-inferior.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  APBI-IMRT Florence
  15yr IBTR 7.7% APBI vs 4.2% WBI, HR 1.57 (0.82-3.04) p=0.17; excess is new primaries, not true local relapse.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  DBCG RT Natural
  5yr invasive LR 1.5% with PBI vs 9.8% randomised no-PBI vs 8.2% self-selected no-PBI; RT+ET arm had zero events.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  EORTC IM-MS (22922/10925)
  20yr OS 61.0% vs 61.8%, HR 1.00 (0.90-1.10), P=0.967: early 15yr survival signal gone, BCM benefit offset by non-BCM deaths.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  IMPORT HIGH
  10yr IBTR 3.5% vs 3.7% vs 5.5% across 40+16Gy, 48Gy SIB, 53Gy SIB; further escalation adds nothing.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  HypoG-01
  118 first events at 4.8y median f/u; LRR infrequent and mostly in-volume, patterns comparable between 40Gy/15fx and 50Gy/25fx.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  DBCG HYPO
  10-yr grade 2-3 breast induration 19.5% with 40Gy/15fx vs 24.7% with 50Gy/25fx, HR 0.76, p=0.005; no recurrence or survival cost.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  Tumour bed boost after BCS + WBRT
  10-yr IBTR 1.2% no-boost vs 1.2% boost in 0-2 risk factors; boost omission viable in modern systemic era.
• New 🫘 Kidney · 2026-05-17 ESTRO Congress 2026
  RCC SBRT local control
  100% local control at 5 years for primary RCC treated with SBRT, per a conference tweet with no denominator.
• New 🎯 Oligometastatic / Mets · 2026-05-17 ESTRO Congress 2026
  OligoCare
  Real-world SABR local in-field progression 5.0% at 1yr, 11.4% at 3yrs across 2447 pts / 3533 lesions; CRC worst.
• New 🎯 Oligometastatic / Mets · 2026-05-17 ESTRO Congress 2026
  EXTEND
  Primary aggregated analysis across all tumor-histology baskets now published in JCO; no effect sizes reported in source tweet.
• New 👄 Head & Neck · 2026-05-17 ESTRO Congress 2026
  DIREKHT
  Contralateral neck sparing and 56 Gy primary CTV de-escalation in selected post-op HNSCC; no effect sizes reported in source tweets.